CARY, N.C., Dec. 6, 2021 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by PharmaEssentia USA Corporation as a specialty pharmacy provider for BESREMi® (ropeginterferon alfa-2b-njft) for the treatment of adults with polycythemia vera (PV).
BESREMi, previously granted Orphan Drug designation, was approved by the U.S. Food and Drug Administration (FDA) on November 12, 2021. This therapy is an innovative monopegylated long-acting interferon intended for injection once every two weeks or once every 4 weeks during long-term maintenance (after achieving hematological stability for at least one year).
“Without proper treatment, polycythemia vera can lead to serious cardiovascular complications, as well as transform to secondary myelofibrosis or leukemia,” said Ashleigh Burdette, senior director of Clinical Innovation at Biologics. “BESREMi gives patients with PV an effective treatment option that not only manages symptom burden, but also targets the disease early. We are excited to offer this therapy to patients.”
Biologics specialty pharmacy is committed to and recognized for its level of customer service as well as its innovative, high-touch and multidisciplinary patient-centric approach. Each team includes pharmacists with in-depth knowledge of therapies, experienced nurses, and financial counselors who are familiar with various financial assistance programs and organizations that help patients. This deeply skilled care team works together to develop individualized care plans that address each patient’s unique clinical, financial and emotional needs and streamlines communication back to the treating provider, enabling high-quality care and differentiated outcomes. In addition, the Biologics team works closely with payers to ensure patients can access the specialty medications they need.
Physicians may submit prescriptions to Biologics via phone (800.850.4306), fax (800.823.4506) or eScribe. For electronic prescribing systems, physicians may search for Biologics within their EMR system.
About Biologics by McKesson
Biologics by McKesson is an independent specialty pharmacy with more than 25 years of experience connecting patients to life-changing medications in oncology and other rare and complex therapeutic areas. Built on the foundation of deep clinical expertise and a high-touch approach to patient care, Biologics delivers seamless access and personalized engagement, so patients get the most out of the care they receive. As a business within McKesson Corporation, Biologics harnesses unparalleled reach and connectivity across the healthcare system to connect the dots between payers, providers and biopharma, so together, they can deliver better care and outcomes for every patient.